Myocardial deformation and cardiac remodeling is influenced by obesity - assessment of myocardial strain by CMR feature tracking in healthy obese

Charité - University Medicine Berlin0 个研究点目标入组 170 人开始时间: 2021年6月10日最近更新: 2022年6月20日

适应症

试验速览

暂无简介。

•1. Age >18 and <60 years
•2. BMI >27 kg/m²
•3. No medication except contraceptives or L-thyroxine
•4. Discontinuation of a chronic medication must be medically justifiable because improvement in the condition for which the medication is being taken can be expected through weight loss

•1. Pregnancy/lactation
•2. Diseases or functional disorders that, in the opinion of the investigator, preclude participation in a clinical trial
•3. Manifest endocrinological or metabolic diseases requiring treatment (diabetes mellitus, hypo- and hyperthyroidism, Cushing's syndrome, M. Cushing syndrome, Cushing's disease); normal TSH with L-thyroxine use is acceptable
•4. Manifest cardiovascular diseases requiring treatment (hypertension like RR > 160/95 mmHg or > two medications; coronary artery disease or previous myocardial infarction; cerebral ischemia or apoplexy; clinically significant diseases of the blood vessels (stenoses of the vessels supplying the brain; renal artery stenoses, pAVK)
•5. Diseases of the kidney, liver, or gastrointestinal tract that require treatment and intestinal tract that require chronic medication
•6. Significant neurological or psychiatric disorders (depression, epilepsy, schizophrenia, bulimia nervosa)
•7. History of bariatric surgery
•8. Known or proven abuse of medication, drugs or alcohol
•9. Tumor diseases; postoperative phase
•10. Acute and chronic infections
•11. Incapacity or circumstances that do not allow the patient to fully understand the nature, meaning, and implications of this study
•12. Metal implants and other contraindications by performing MRI (body weight > 130 kg)

发起方